Jennifer A Hollywood1, Aneta Przepiorski2, Randall F D'Souza3, Sreevalsan Sreebhavan4, Ernst J Wolvetang5, Patrick T Harrison6, Alan J Davidson7, Teresa M Holm1. 1. Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand a.davidson@auckland.ac.nz t.holm@auckland.ac.nz j.hollywood@auckland.ac.nz. 2. Department of Developmental Biology, University of Pittsburgh, Pennsylvania. 3. Discipline of Nutrition, The University of Auckland, Auckland, New Zealand. 4. Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand. 5. Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, Australia. 6. Department of Physiology, Biosciences Institute, University College Cork, Cork, Ireland. 7. Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand.
Abstract
BACKGROUND: Mutations in CTNS-a gene encoding the cystine transporter cystinosin-cause the rare, autosomal, recessive, lysosomal-storage disease cystinosis. Research has also implicated cystinosin in modulating the mTORC1 pathway, which serves as a core regulator of cellular metabolism, proliferation, survival, and autophagy. In its severest form, cystinosis is characterized by cystine accumulation, renal proximal tubule dysfunction, and kidney failure. Because treatment with the cystine-depleting drug cysteamine only slows disease progression, there is an urgent need for better treatments. METHODS: To address a lack of good human-based cell culture models for studying cystinosis, we generated the first human induced pluripotent stem cell (iPSC) and kidney organoid models of the disorder. We used a variety of techniques to examine hallmarks of cystinosis-including cystine accumulation, lysosome size, the autophagy pathway, and apoptosis-and performed RNA sequencing on isogenic lines to identify differentially expressed genes in the cystinosis models compared with controls. RESULTS: Compared with controls, these cystinosis models exhibit elevated cystine levels, increased apoptosis, and defective basal autophagy. Cysteamine treatment ameliorates this phenotype, except for abnormalities in apoptosis and basal autophagy. We found that treatment with everolimus, an inhibitor of the mTOR pathway, reduces the number of large lysosomes, decreases apoptosis, and activates autophagy, but it does not rescue the defect in cystine loading. However, dual treatment of cystinotic iPSCs or kidney organoids with cysteamine and everolimus corrects all of the observed phenotypic abnormalities. CONCLUSIONS: These observations suggest that combination therapy with a cystine-depleting drug such as cysteamine and an mTOR pathway inhibitor such as everolimus has potential to improve treatment of cystinosis.
BACKGROUND: Mutations in CTNS-a gene encoding the cystine transporter cystinosin-cause the rare, autosomal, recessive, lysosomal-storage disease cystinosis. Research has also implicated cystinosin in modulating the mTORC1 pathway, which serves as a core regulator of cellular metabolism, proliferation, survival, and autophagy. In its severest form, cystinosis is characterized by cystine accumulation, renal proximal tubule dysfunction, and kidney failure. Because treatment with the cystine-depleting drug cysteamine only slows disease progression, there is an urgent need for better treatments. METHODS: To address a lack of good human-based cell culture models for studying cystinosis, we generated the first human induced pluripotent stem cell (iPSC) and kidney organoid models of the disorder. We used a variety of techniques to examine hallmarks of cystinosis-including cystine accumulation, lysosome size, the autophagy pathway, and apoptosis-and performed RNA sequencing on isogenic lines to identify differentially expressed genes in the cystinosis models compared with controls. RESULTS: Compared with controls, these cystinosis models exhibit elevated cystine levels, increased apoptosis, and defective basal autophagy. Cysteamine treatment ameliorates this phenotype, except for abnormalities in apoptosis and basal autophagy. We found that treatment with everolimus, an inhibitor of the mTOR pathway, reduces the number of large lysosomes, decreases apoptosis, and activates autophagy, but it does not rescue the defect in cystine loading. However, dual treatment of cystinotic iPSCs or kidney organoids with cysteamine and everolimus corrects all of the observed phenotypic abnormalities. CONCLUSIONS: These observations suggest that combination therapy with a cystine-depleting drug such as cysteamine and an mTOR pathway inhibitor such as everolimus has potential to improve treatment of cystinosis.
Authors: Martijn J Wilmer; Leo A J Kluijtmans; Thea J van der Velden; Peter H Willems; Peter G Scheffer; Rosalinde Masereeuw; Leo A Monnens; Lambertus P van den Heuvel; Elena N Levtchenko Journal: Biochim Biophys Acta Date: 2011-02-28
Authors: Benjamin R Underwood; Sara Imarisio; Angeleen Fleming; Claudia Rose; Gauri Krishna; Phoebe Heard; Marie Quick; Viktor I Korolchuk; Maurizio Renna; Sovan Sarkar; Moisés García-Arencibia; Cahir J O'Kane; Michael P Murphy; David C Rubinsztein Journal: Hum Mol Genet Date: 2010-06-21 Impact factor: 6.150
Authors: Amer Jamalpoor; Charlotte Agh van Gelder; Fjodor A Yousef Yengej; Esther A Zaal; Sante P Berlingerio; Koenraad R Veys; Carla Pou Casellas; Koen Voskuil; Khaled Essa; Carola Me Ammerlaan; Laura Rita Rega; Reini En van der Welle; Marc R Lilien; Maarten B Rookmaaker; Hans Clevers; Judith Klumperman; Elena Levtchenko; Celia R Berkers; Marianne C Verhaar; Maarten Altelaar; Rosalinde Masereeuw; Manoe J Janssen Journal: EMBO Mol Med Date: 2021-06-24 Impact factor: 12.137
Authors: Fjodor A Yousef Yengej; Jitske Jansen; Maarten B Rookmaaker; Marianne C Verhaar; Hans Clevers Journal: Cells Date: 2020-05-26 Impact factor: 6.600